Collegium Pharmaceutical Q1 2025 Earnings Report

Collegium Pharmaceutical EPS Results

• Actual EPS: N/A
• Consensus EPS: $1.50
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Collegium Pharmaceutical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $174.96 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Collegium Pharmaceutical Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: After Market Closes
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 4:30PM ET

Collegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.